Breaking News

Stiefel Licenses Toctino from Basilea

Stiefel to take over development and distribution agreements

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Basilea Pharmaceutica has entered into an exclusive worldwide agreement with GSK subsidiary Stiefel for Toctino (alitretinoin). Stiefel will assume responsibility for the development, manufacturing, commercialization, and distribution of the product and will take over distribution agreements in Europe, Canada, Mexico, Israel and the Republic of Korea.   Toctino was developed by Basilea and is commercially available in 14 countries and approved in an additional 15 countries for the treatment of a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters